Parkwalk closes investment in Horizon Discovery for the University of Cambridge Enterprise Fund I
Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.
Horizon aspires to provide solutions that unlock the promise of the human genome project for the benefit of scientific researchers, patients and society; provide powerful research tools to advance the development of personalized medicines; provide molecular reference standards and support better healthcare outcomes for patients.
